A two-step approach pooled indication-specific response rates, then generated naïve odds ratios via random-effects models, reflecting limited head-to-head evidence across BTK inhibitors. Across ...
NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical ...
SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...
Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) ...
Glucocorticoids and B-cell targeting therapies are the cornerstones of IgG4 disease treatment, according to data presented at ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...
Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint: Basel Wednesday, March 4, 2026, 14:00 Hrs [IST] Roc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results